2023年5月19日,

費城,賓夕法尼亞州,美國費城,5月19日,2023(全球通訊社)——球探生物,生物科技公司發展中蛋白質和一次性AAV基因療法主要治療慢性寵物健康狀況,今天宣布,執行官馬克·霍夫曼和安妮traa一起聯合創始人Matthew Wilson將出席第26屆美國社會的基因和細胞治療(ASGCT)峰會在洛杉磯,加州在2023年5月20日。童子軍生物首席執行官馬克·霍夫曼博士將概述動物健康產業的異同從人類健康。星期六,5月20日在8:11點。PST。童子軍生物首席發展官安妮•traa數字式電壓表DACT女士將討論疾病跡象在動物健康:一個醫學基因治療方法。星期六,5月20日上午9點55分。PST。童子軍生物聯合創始人馬特·威爾遜將細節CMC策略——減少動物衛生市場的商品成本。星期六,5月20日在上午10:20。PST。所有三個將參加周六11 am-12pm小組討論。關於ASGCT基因和細胞治療的美國社會是主要的專業會員組織基因和細胞治療。社會的成員是科學家,醫生,病人的倡導者,和其他專業人士。 Members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease. About Scout Bio Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies and monoclonal antibodies for major chronic pet health conditions. Scout Bio’s therapies are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of genetic medicine research. Scout Bio is a private company headquartered in Philadelphia, Pennsylvania. For more information, see www.scoutbio.co . For further information, please contact: Fran Gaconnier